

Exhibit 24

G.P. Allaway et al., U.S. Serial No. 10/763,545, filed January 23, 2004

Pending claims:

78. A method of treating a subject afflicted with HIV-1 which comprises administering to the subject an effective dose of a monoclonal antibody or a fragment thereof comprising complementarity determining regions (CDRs), said CDRs binding to an epitope of chemokine receptor 5 (CCR5), which epitope comprises consecutive amino acid residues present in a) an N-terminus of CCR5, b) one of three extracellular loop regions of CCR5, or c) a combination of (a) and (b), so as to treat the subject.
79. A method of preventing a subject from contracting HIV-1 which comprises administering to the subject an effective dose of a monoclonal antibody or a fragment thereof comprising complementarity determining regions (CDRs), said CDRs binding to an epitope of chemokine receptor 5 (CCR5), which epitope comprises consecutive amino acid residues present in a) an N-terminus of CCR5, b) one of three extracellular loop regions of CCR5, or 3) a combination of (a) and (b), so as to prevent the subject from contracting HIV-1.
80. The method of claim 78 or 79, wherein the antibody is selected from the group consisting of antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), antibody PA12 (ATCC Accession No. HB-12609) and antibody PA14 (ATCC Accession No. HB-12610).

81. The method of claim 78 or 79, wherein the antibody or fragment thereof binds to the same epitope as antibody PA14 (ATCC Accession No. HB-12610).
82. The method of claim 78 or 79, wherein the complementarity determining regions of the antibody or the fragment thereof are derived from a hybridoma having ATCC Accession No. HB-12610 (PA14).
83. The method of claim 78 or 79 wherein the antibody or fragment thereof is humanized.
84. The method of claim 83, wherein the antibody comprises a framework from a human immunoglobulin molecule.
85. The method of claim 84, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
86. The method of claim 81, wherein the antibody or fragment thereof is humanized.
87. The method of claim 86, wherein the antibody comprises a framework from a human immunoglobulin molecule.
88. The method of claim 87, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
89. The method of claim 82, wherein the antibody or fragment thereof is humanized.

90. The method of claim 89, wherein the antibody comprises a framework from a human immunoglobulin molecule,
91. The method of claim 90, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
92. The method of claim 78 or 79, wherein the antibody or fragment thereof is labeled with a detectable marker.
93. The method of claim 92, wherein the detectable marker is a radioactive marker or a fluorescent marker.
94. The method of claim 78 or 79, wherein the antibody or fragment thereof is administered in a pharmaceutically acceptable carrier.
95. The method of claim 78 or 79, wherein the dose of the antibody or fragment thereof is 0.1 to 100,000 $\mu\text{g/kg}$ body weight of the subject.
96. The method of claim 78 or 79, wherein the dose is administered by a route selected from the group consisting of oral, rectal, intra-vaginal, topic, nasal, ophthalmic and parenteral routes of administration.
97. The method of claim 96, wherein the parenteral route comprises subcutaneous, intramuscular, intravenous or intra-sternal administration.
98. The method of claim 78 or 79, wherein multiple doses are administered to the subject.

99. A composition which comprises a therapeutically effective dose of a monoclonal antibody or a fragment thereof comprising complementarity determining regions (CDRs), said CDRs binding to an epitope of chemokine receptor 5 (CCR5), which epitope comprises consecutive amino acids present in a) an N-terminus of CCR5, b) one of three extracellular loop regions of CCR5, or c) a combination of (a) and (b); and a pharmaceutically acceptable carrier.
100. The composition of claim 99, wherein the antibody is selected from the group consisting of antibody PA8 (ATCC Accession No. HB-12605), antibody PA9 (ATCC Accession No. HB-12606), antibody PA10 (ATCC Accession No. HB-12607), antibody PA11 (ATCC Accession No. HB-12608), antibody PA12 (ATCC Accession No. HB-12609), antibody PA14 (ATCC Accession No. HB-12610).
101. The composition of claim 99, wherein the antibody or fragment thereof binds to the same epitope as antibody PA14 (ATCC Accession No. HB-12610).
102. The composition of claim 99, wherein the complementarity determining regions of the antibody or fragment thereof are derived from a hybridoma having ATCC Accession No. HB-12610 (PA14).
103. The composition of any one of claims 99, 100, 101 and 102 wherein the antibody or fragment thereof is humanized.
104. The composition of claim 103, wherein the antibody comprises a framework from a human immunoglobulin molecule.

105. The composition of claim 104, wherein the human immunoglobulin molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA and IgM.
106. The composition of claim 99, wherein the antibody or fragment thereof is labeled with a detectable marker.
107. The composition of claim 106, wherein the detectable marker is a radioactive marker or a fluorescent marker.
108. The composition of claim 99, wherein the composition further comprises at least one additive selected from the group consisting of antimicrobials, antioxidants, chelating agents and inert gasses.